Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity

Expert Opinion on Investigational Drugs

Volumn 20, Issue 1, 2011, Pages 23-39

  Leishman, Andrew J ^a   Sims, Gary P ^b   Sleeman, Matthew ^b   Braddock, Martin ^a  

^a ASTRAZENECA   (United Kingdom)

^b MEDIMMUNE   (United States)

Author keywords

autoimmunity; biological; clinic; small molecule; target; therapy

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; AIN 457; AMG 827; ATACICEPT; BELIMUMAB; BENLYSTA; BRIAKINUMAB; CAM 3001; DV 1179; EPRATUZUMAB; FOSTAMATINIB; IMMUNOLOGIC AGENT; IMO 3100; INCB 28050; KS 003; LY 2127399; LY 2439821; MDX 1342; MOR 103; OCRELIZUMAB; OFATUMUMAB; PD 360324; PF 004171327; PLACEBO; RG 7416; RITUXIMAB; RONTALIZUMAB; SIFALIMUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB; VX 509;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ANEMIA; ANKYLOSING SPONDYLITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BEHCET DISEASE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; CROHN DISEASE; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; FATIGUE; HUMAN; HYPERTENSION; IMMUNOPATHOGENESIS; INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MULTIPLE SCLEROSIS; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; NOSE CONGESTION; OPPORTUNISTIC INFECTION; OROPHARYNGEAL PAIN; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIASIS VULGARIS; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SJOEGREN SYNDROME; SORE THROAT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; UVEITIS;

ANIMALS; ANTIGENS, CD; AUTOIMMUNE DISEASES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-6; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650262444     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.540569     Document Type: Article

References (128)

1. Romagnani S. Immunological tolerance and autoimmunity. Intern Emerg Med 2006;1(3):187-96
2. Autoimmune treatment (2009-2014). Available from: www.reportlinker.com/ p0148004/Autoimmune-Treatment.html? v=2 [Last accessed 02 July 2010]
3. Gabriel S, Crowson CS, Maradit Kremers H, Therneau TM. The rising incidence of rheumatoid arthritis [abstract 773]. ACR 24 - 29 October 2008; San Francisco, CA
4. AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage Development Product - Fostamatinib Disodium (R788) - for the Treatment of Rheumatoid Arthritis. Available from: http://www.astrazeneca.com/ media/latest-press-releases/rigel-licensing? itemId=8539858 [Last accessed 02 July 2010]
5. Leung BP, Culshaw S, Gracie JA, et al. A role for IL-18 in neutrophil activation. J Immunol 2001;167(5):2879-86
6. Emery P, Kvien TK, Combe B, et al. [LB0001] very early (<4 months) treatment with combination etanercept (ETN) and methotraxate (MTX) produces significantly better remision rates: Results from the COMET study. Ann Rheum Dis 2010;69(suppl. 3):57
7. Suryaprasad AG, Prindiville T. The biology of TNF blockade. Autoimmun Rev 2003;2(6):346-57
8. Delavallee L, Semerano L, Assier E, et al. Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis. Arthritis Res Ther 2009;11(6):R195
9. Cronstein BN. Interleukin-6- a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65(Suppl 1):S11-15
10. Yanaba K, Bouaziz JD, Matsushita T, et al. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008;223:284-99
11. St Clair EW. Novel targeted therapies for autoimmunity. Curr Opin Immunol 2009;21(6):648-57
12. European Medicines Agency information on abatacept. Available from: http://www.ema.europa.ema/index.jsp?curl=pages/medicines/human/medicines/000701/ human-med-000958.jsp&murl=menus/medicines/medicines.jsp&mid= WC0b01ac058001d124&jsenabled=true [Last accessed 02 October 2010]
13. Genant HK, Peterfy CG, Westhovens R, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008;67:1084-9
14. Westhovens R, Robles M, Nayiager S, Wollenhaupt J, et al. Disease remission is achieved within two years in over half of methotrexate naive patients with early erosive rheumatoid arthritis (RA) treated with abatacept plus MTX: results from the AGREE Trial [abstract]. Arthritis Rheum 2009;60(Suppl 10):638
15. Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis (ACCESS). Available from: http://clinicaltrials.gov/ct2/show/NCT00774852?term= ACCESS&rank=10 [Last accessed 02 July 2010]
16. Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;(4):CD007848
17. Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010;9:325-38
18. Khraishi M. Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol Suppl 2009;82:25-32
19. Platanias LC. Mechanisms of type I and type II interferon mediated signalling. Nat Rev Immunol 2005;5(5):375-86
20. Hooks JJ, Moutsopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;301(1):5-8
21. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982;25(4):401-6
22. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006;25(3):383-92
23. Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006;18(6):676-82
24. Mathian A, Weinberg A, Gallegos M, et al. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol 2005;174(5):2499-506
25. Santiago-Raber ML, Baccala R, Haraldsson KM, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003;197(6):777-88
26. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197(6):711-23
27. Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54(9):2951-62
28. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000;43(7):1431-42
29. Ronnblom L, Alm GV. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 2001;22(8):427-31
30. Guiducci C, Gong M, Xu Z, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010;465:937-41
31. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60(6):1785-96
32. McBride JM, Wallace DJ, Yao Z, et al. Dose-dependent modulation of interferon regulated genes with administration of single and repeat doses of rontalizumab in a phase I, placebo controlled, double blind, dose escalation study in SLE. Arthritis Rheum 2009;60:S775-6
33. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228(1):273-87
34. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Ann Rev Immunol 1998;16:293-322
35. Malemud CJ. Suppression of autoimmune arthritis by small molecule inhibitors of the JAK/STAT pathway. Pharmaceuticals 2010;3:1446-55
36. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 2010;24(4):513-26
37. Kremer JM, Cohen S, Wilkinson B, et al. Safety and efficacy after 24 week (WK) dosing of the oral JAK inhibitor CP-690,550 (CP) in combination with methotrexate (MTX) in patients (PTS) with active rheumatoid arthritis (RA). ACR, Philadelphia; 17 - 21 October 2009. p. 1925
38. Fleischmann RM, Genovese MC, Gruben D, et al. Safety and efficacy after 24 week (wk) dosing of the oral JAK inhibitor CP-690,550 (CP) as monotherapy in patients (pts) with active rheumatoid arthritis (RA). ACR, Philadelphia; 17 - 21 October 2009. p. 1924
39. Long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Available from: http://clinicaltrials.gov/ct2/show/ NCT00413699 [Last accessed 02 July 2010]
40. Long-term, open-label study of CP-690,550 for treatment of rheumatoid arthritis in Japan. Available from: http://clinicaltrials.gov/ct2/show/ NCT00661661 [Last accessed 05 September 2010]
41. Hennessy EJ, Parker AE, O'Neill LA. Targeting toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010;9(4):293-307
42. Gilliet M, Cao W, Liu Y-J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008;8:594-606
43. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416(6881):603-7
44. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13:552-9
45. Lipford G, Forsbach A, Zepp C, et al. Selective toll-like receptor 7/8/9 antagonists for the oral treatment of autoimmune diseases [abstract 1596]. ACR 6 - 11 November 2009; Boston, MA
46. Barrat FJ, Meeker T, Gregorio J, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202:1131-9
47. Barrat FJ, Meeker T, Chan JH, et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007;37(12):3582-6
48. DV1179. Available from: http://www.dynavax.com/autoimmunity.html [Last accessed 13 July 2010]
49. IMO-3100. Available from: http://www.iderapharma.com/development/imo- 3100.php [Last accessed 02 July 2010]
50. Zhu F-G, Dong Y, Kandimalla ER, Agrawal S. Studies of combination of IMO-3100, an antagonist of TLR7 and TLR9, and etanercept, a TNF- inhibitor, in a mouse model of collagen-induced arthritis (CIA). Arthritis Rheum 2009;60(Suppl 10):659
51. Dorner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Arthritis Res Ther 2009;11(5):247
52. Marston B, Palanichamy A, Anolik JH. B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol 2010;22(3):307-15
53. Sousa E, Isenberg D. Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies. Best Pract Res Clin Rheumatol 2009;23:563-74
54. Looney RJ, Anolik J, Sanz I. A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol 2010;20:1-10
55. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. (EXPLORER). Arthritis Rheum 2010;62(1):222-33
56. U.S. Food and Drug Administration (FDA). Rituxan warning. FDA Consum 2007;41:3
57. Ocrelizumab. Available from: http://www.roche.com/media/media-releases/ med-cor-2010-03-08.htm [Last accessed 13 July 2010]
58. Carnahan J, Wang P, Kendall R, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 2003;9:3982s-90s
59. Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006;8:R129
60. Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74
61. Cardarelli PM, Blanset D, Rao-Naik C, et al. A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for treatment of autoimmune diseases [abstract]. Arthritis Rheum 2009;60(10):692
62. Nagorsen D, Bargou R, Ruttinger D, et al. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma 2009;50:886
63. Vallera DA, Chen H, Sicheneder AR, et al. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res 2009;33(9):1233-42
64. Belnoue E, Pihlgren M, McGaha TL, et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008;111:2755-64
65. Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3:822-9
66. Treml LS, Carlesso G, Hoek KL, et al. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J Immunol 2007;178(12):7531-9
67. Groom JR, Fletcher CA, Walters SN, et al. BAFF and MyD88 signals promote a lupus like disease independent of T cells. J Exp Med 2007;204:1959-71
68. Mackay F, Leung H. The role of the BAFF/APRIL system on T cell function. Semin Immunol 2006;18:284-9
69. Mackay F, Schneider P, Rennert P, Browning JL. BAFF and APRIL: a tutorial on % cell survival. Annu Rev Immunol 2003;21:231-64
70. Ramanujam M, Davidson A. BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled? Immunol Rev 2008;223:156-7
71. Mackay F, Sierro F, Grey ST, Gordon TP. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005;8:243-65
72. Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10(5):R109
73. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61(9):1168-78
74. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51
75. Mok CC. Update on emerging drug therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs 2010;15(1):53-70
76. Navarra S, Guzman R, Gallacher A, et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. ACR, Philadelphia; 17 - 21 October 2009. p. LB1
77. Chatham W, Furie R, Petri M, et al. Belimumab (fully human monoclonal antibody to BLyS) improved or stabilized systemic lupus erythematosus (SLE) disease activity over 3 years of therapy. ACR, San Francisco; 25 - 29 October 2008. p. 1094
78. Genovese MC. Phase 2 study of safety and efficacy of a novel anti-BAFF monoclonal antibody, in patients with RA treated with methotrexate (MTX). ACR, Philadelphia; 17 - 21 October 2009. p. 1923
79. Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007;56(12):4142-50
80. Pena-Rossi C, Nasonov E, Stanislav M, et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 2009;18(6):547-55
81. Tak PP, Thurlings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008;58(1):61-72
82. Nestorov I, Papasouliotis O, Pena Rossi C, Munafo A. Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. J Pharm Sci 2010;99:524-38
83. Cohen S, Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol 2010;22(3):330-5
84. Riccaboni M, Bianchi I, Petrillo P. Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov Today 2010. doi:10.1016/j.drudis. 2010.05.001
85. Weinblatt M, Kavanaugh A, Genovese M, et al. An oral spleen tyrosine kinase (syk) inhibitor for rheumatoid arthritis. NEJM 2010;363(14):1303-12
86. Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: a 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed biologic agents. Arthritis Rheum 2010: DOI 10.1002/art.30114
87. Song IH, Gold R, Straub RH, et al. New glucocorticoids on the horizon: repress, don't activate! J Rheumatol 2005;32(7):1199-1207
88. Stock T, Fleishaker D, Mukherjee A, et al. Evaluation of safety, pharmacokinetics and pharmacodynamics of a selective glucocorticoid receptor modulator (SGRM) in healthy volunteers. ACR, Philadelphia; 17 - 21 October 2009. p. 420
89. Gerlag DM, Haringman JJ, Smeets TJ, et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004;50(12):3783-91
90. Campbell IK, Rich MJ, Bischof RJ, et al. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol 1998;161(7):3639-44
91. Campbell IK, Rich MJ, Bischof RJ, Hamilton JA. The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF. J Leukoc Biol 2000;68(1):144-50
92. Lawlor KE, Campbell IK, Metcalf D, et al. Critical role for granulocyte colony-stimulating factor in inflammatory arthritis. Proc Natl Acad Sci USA 2004;101:11398-403
93. Cornish AL, Campbell IK, McKenzie BS, et al. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009;5(10):554-9
94. Huston A, Lyman GH. Agents under investigation for the treatment and prevention of neutropenia. Expert Opin Investig Drugs 2007;16(11):1831-40
95. Hayat SQ, Hearth-Holmes M, Wolf RE. Flare of arthritis with successful treatment of Felty's syndrome with granulocyte colony stimulating factor (GCSF). Clin Rheumatol 1995;14(2):211-12
96. Hazenberg BP, Van Leeuwen MA, Van Rijswijk MH, et al. Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood 1989;74(8):2769-70
97. De Vries EG, Willemse PH, Biesma B, et al. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet 1991;338(8765):517-18
98. Burmester GR, Wagner F, Feist E, et al. Cam-3001; a novel human monoclonal antibody against GM-CSFR, in subjects with rheumatoid arthritis (RA): results of a PhI Study. ACR, Philadelphia; 17 - 21 October 2009. p. 1926
99. Mackay F, Majeau GR, Lawton P, et al. Lymphotoxin but not tumor necrosis factor functions to maintain splenic architecture and humoral responsiveness in adult mice. Eur J Immunol 1997;27(8):2033-42
100. Fava RA, Notidis E, Hunt J, et al. A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis. J Immunol 2003;171(1):115-26
101. Browning JL. Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunol Rev 2008;223:202-20
102. Isaacs D, Genovese MC, Emery P, et al. Efficacy and safety of baminercept in the treatment of rheumatoid arthritis (RA) - preliminary results of the phase 2b study in the DMARD-IR population. ACR, Philadelphia; 17 - 21 October 2009. p. 416
103. Chiang EY, Kolumam GA, Yu X, et al. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 2009;15(7):766-73
104. Vila J, Isaacs JD, Anderson AE. Regulatory T cells and autoimmunity. Curr Opin Hematol 2009;16(4):274-9
105. Koenders MI, van den Berg WB. Translational mini-review series on Th17 cells: are T helper 17 cells really pathogenic in autoimmunity? Clin Exp Immunol 2010;159(2):131-6
106. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol 2010;28:445-89
107. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003;171(11):6173-7
108. Lubberts E, Koenders MI, Oppers-Walgreen B, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004;50(2):650-9
109. Bush KA, Farmer KM, Walker JS, Kirkham BW. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 2002;46(3):802-5
110. Nakae S, Saijo S, Horai R, et al. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003;100(10):5986-90
111. Hirota K, Hashimoto M, Yoshitomi H, et al. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med 2007;204(1):41-7
112. Van Den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009, 5, 10, 549-53
113. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010;129(3):311-21
114. Goldberg M, Nadiv O, Luknar-Gabor N, et al. Synergism between tumor necrosis factor alpha and interleukin-17 to induce IL-23 p19 expression in fibroblast-like synoviocytes. Mol Immunol 2009;46(8-9):1854-9
115. Guilloteau K, Paris I, Pedretti N, et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, Oncostatin M, IL-1{alpha}, and TNF-{alpha} recapitulates some features of psoriasis. J Immunol 2010;184:5263-70
116. Nalbandian A, Crispin JC, Tsokos GC. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 2009;157(2):209-15
117. Brucklacher-Waldert V, Stuerner K, Kolster M, et al. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009;132(Pt 12):3329-41
118. Sloan-Lancaster J, Genovese MC, Roberson SA, Van den Bosch F. Safety, tolerability and evidence of efficacy of intravenous LY2439821 in patients with rheumatoid arthritis receiving background oral DMARDS [abstract OP-0160]. EULAR 2009; Copenhagan, Denmark
119. Durez P, Chindalore V, Wittmer B, et al. AIN457, an anti-IL17 antibody, shows good safety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate therapy in a randomized, double-blind proof-of-concept trial [abstract LB0002]. EULAR 2009; Copenhagan, Denmark
120. Mus AM, Cornelissen F, Asmawidjaja PS, et al. Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of interleukin-22, but not interleukin-21, in autoimmune experimental arthritis. Arthritis Rheum 2010;62(4):1043-50
121. Kimura A, Naka T, Kishimoto T. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci USA 2007;104(29):12099-104
122. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006;176(3):1908-15
123. Hedrick MN, Lonsdorf AS, Shirakawa AK, et al. CCR6 is required for IL-23- induced psoriasis-like inflammation in mice. J Clin Invest 2009;119(8):2317-29
124. Leonardi CL, Kimball AB, Papp KA, et al.; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371(9625):1665- 1674
125. Papp KA, Langley RG, Lebwohl M, et al.; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371(9625):1675- 84
126. Ryan C, Thrash B, Warren RB, Menter A. The use of ustekinumab in autoimmune disease. Expert Opin Biol Ther 2010;10(4):587-604
127. Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 2010;160(4):810-20
128. Burakoff R, Barish CF, Riff D, et al. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis 2006;12(7):558-65